Inhibrx Biosciences (INBX) Other Non Operating Income (2023 - 2026)
Inhibrx Biosciences (INBX) posted quarterly Other Non Operating Income of -$39000.0 for Q4 2025, down 165.0% year-over-year from $60000.0 in Q4 2024, and up 15.22% quarter-over-quarter from -$46000.0 in Q3 2025.
Powered by 
Analysis
Inhibrx Biosciences (INBX) Other Non Operating Income (2023 - 2026) Analysis & Trends
Inhibrx Biosciences (INBX) has reported Other Non Operating Income for 3 consecutive years, with -$39000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non Operating Income fell 165.0% year-over-year to -$39000.0; the TTM figure through Dec 2025 stood at -$381000.0 (down 608.0% YoY), while the FY2025 annual figure was -$381000.0, down 608.0% from the prior year.
- Other Non Operating Income climbed to -$39000.0 in Q4 2025 per INBX's latest filing, from -$46000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $60000.0 in Q4 2024 and bottomed at -$246000.0 in Q2 2025.
- Historically, Other Non Operating Income has averaged -$74181.8 across 3 years, with a median of -$50000.0 in 2025.
- Annual changes were most pronounced in 2024 — Other Non Operating Income jumped 137.97% — and 2025, when it sank 845.45%.
- Inhibrx Biosciences' Other Non Operating Income stood at -$158000.0 in 2023, then surged by 137.97% to $60000.0 in 2024, then tumbled by 165.0% to -$39000.0 in 2025.
- Business Quant data shows INBX's Other Non Operating Income at -$39000.0 in Q4 2025, -$46000.0 in Q3 2025, and -$246000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Inhibrx Biosciences | 1.91 Bn | 1.91 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -68,000.00 |
| Dec 31, 2025 | -39,000.00 |
| Sep 30, 2025 | -46,000.00 |
| Jun 30, 2025 | -246,000.00 |
| Mar 31, 2025 | -50,000.00 |
| Dec 31, 2024 | 60,000.00 |
| Sep 30, 2024 | 41,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Mar 31, 2024 | -59,000.00 |
| Dec 31, 2023 | -158,000.00 |
| Sep 30, 2023 | -135,000.00 |
| Jun 30, 2023 | -217,000.00 |